

Site selection from EPAD network complete

Publishable Summary

In order to improve the chances of success for clinical trials of AD prevention, the Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) will be conducted connected to the European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS). Amyloid PET imaging in AMYPAD PNHS will provide a relevant imaging biomarker dimension complementary to CSF amyloid, and will complement the phenotyping and disease modelling efforts of EPAD LCS.

EPAD LCS sites need to be eligible to participate in AMYPAD PNHS, and this eligibility will be defined based on:

1. Access to PET facilities
2. Access to radiotracer manufacturing facilities
3. Access to sufficient research participants

After eligibility is defined, the process of certification is started to ensure harmonized data quality and imaging procedures between sites. Both processes will be performed in waves, with priority given to EPAD LCS sites already participating in AMYPAD, as well as those with high recruitment rates.

This document describes and summarizes the rationale behind certifying EPAD LCS sites to participate in AMYPAD PNHS, as well as strategies for mitigating risks related to low recruitment rates.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

